{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.1","upperLimit":"22.2","value":"12.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Analyzed using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive tivantinib 360 PO BID. Treatment continues in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Tivantinib)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}